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Cancer survival in England and Wales has improved over the last 30 years. However, cohort survival estimates delay recognition of
these improvements. Here we show that period survival estimates, based on survival in a recent time period, suggest a more
optimistic pattern for England and Wales than cohort-based measures for most cancers.
British Journal of Cancer (2003) 89, 74–76. doi:10.1038/sj.bjc.6600976 www.bjcancer.com
& 2003 Cancer Research UK
Keywords: period survival; cancer relative survival
                        
Cancer survival in England and Wales has generally improved
over the last 30 years. However, conventional survival estimates,
based on following-up patient cohorts, delay identification of these
improvements. Period analysis is a method of obtaining more up-
to-date estimates of survival, calculated using only survival
experience in a recent time period (Brenner and Gefeller, 1996).
US and European data have shown these estimates to be good
predictors of long-term survival (Brenner and Hakulinen, 2001;
Brenner, 2002). Here cancer registry data are used to compare 5-
and 10-year relative survival estimates for England and Wales
using standard cohort methods and period analysis.
MATERIALS AND METHODS
Data were analysed from the public-use data set of all England and
Wales registrations for 1 January 1981 to 31 December 1990 of the
26 most common cancers (Coleman et al, 1999) (followed until 31
December 1995). We present 5- and 10-year relative survival
estimates for all ages using conventional cohort-based methods
and period analyses. Results are presented for males and females
combined, apart from results for prostate, testis and gynaecolo-
gical cancers.
A cohort-based analysis is defined by the time interval in which
patients are diagnosed. These patients (and only these) are
followed up for 5 or 10 years and survival estimates are calculated.
Here cohort estimates for 5 and 10 years are based on patients
diagnosed between 1986–1990 and 1981–1985, respectively,
and followed up until 1995 (see Table 1). In contrast, period
analyses are defined by a recent time interval in which patients’
survival experience is observed. It excludes short-term survival
of patients diagnosed before the start of the period but includes
their long-term survival within the period. Short-term survival
of more recently diagnosed patients is included (see Brenner
and Gefeller (1996)). Period estimates for 5 and 10 years are based
on patients diagnosed between 1986–1990 and 1981–1990,
respectively, but only include survival experience from 1990 to
1995 (Table 1).
Survival rates presented here are relative survival rates,
adjusting for the general population background mortality. We
calculated the expected survival using Hakulinen’s (1982) method
with 95% confidence intervals. A publicly available macro was
used to calculate both cohort and period estimates (Brenner et al.,
2002).
RESULTS
Table 2 shows that period estimates were higher than cohort
estimates for 22 (85%) of the 26 cancers for 10-year survival and 18
(69%) of the 26 cancers for 5-year survival. This indicates recent
changes in survival that are not detected by standard cohort
analyses. At 10 years, period estimates exceeded cohort estimates
by over 4% for colon, melanoma of the skin, breast, cervix, thyroid
and Hodgkin’s disease. Differences at 5 years were less marked but
largest differences were seen for thyroid and Hodgkin’s disease.
Larger differences between cohort and period estimates were seen
among cancers with better outcomes (10-year survival 450%). In
contrast, where survival was poor (10-year survival o10%),
differences between the estimates were smaller and for four of
these six cancers, survival estimates were lower for period analysis.
DISCUSSION
These results provide the most up-to-date estimates of cancer
survival in England and Wales. Period survival estimates suggest a
more optimistic pattern of cancer survival than cohort-based
measures for the majority of cancers despite variations in survival.
These differences appear greater for cancers with better outcomes.
Our results show similar increases in survival estimates using
period analysis as seen in the USA (Brenner, 2002), but with
differing site-specific patterns.
Period estimates are similar to cohort estimates where cancer
survival patterns have not changed over time. Where survival has
changed, period estimates are more up-to-date. Cohort estimates
are more influenced by short-term survival of patients diagnosed
earlier in a study. If short-term survival changes over time, period
analysis allows for these differences. Received 18 February 2003; accepted 5 March 2003
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patterns of cancer survival are likely to have changed further.
Period analyses of more recent data, when available, are likely to
provide the earliest estimates of these developing patterns.
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Table 1 Intervals of diagnosis and follow-up included in estimates of 5-
and 10 year relative survival for cohort and period analysis
Cohort analysis Period analysis
Survival Diagnosis Follow-up Diagnosis Follow-up
5 years 1986–1990 1986–1995 1986–1990 1990–1995
10 years 1981–1985 1981–1995 1981–1990 1990–1995
Table 2 Five and 10- year relative survival estimates (and 95% confidence intervals) for England and
Wales, by cancer site using cohort and period survival methods
10 years 5 years
Cohort Period Cohort Period
Diagnosed 1981–1985 1981–1990 1986–1990 1986–1990
Followed up 1981–1995 1990–1995 1986–1995 1990–1995
Cancer site
Oral cavity and pharynx 29.4% 30.3% 37.6% 37.7%
28.1%,30.7% 28.7%,31.9% 36.4%,38.8% 35.9%,39.5%
Oesophagus 6.2% 5.3% 7.3% 5.8%
5.7%,6.7% 4.8%,5.8% 6.9%,7.7% 5.3%,6.3%
Stomach 9.1% 9.4% 11.1% 10.2%
8.7%,9.5% 8.9%,9.9% 10.8%,11.4% 9.7%,10.7%
Colon 34.8% 39.2% 40.3% 42.0%
34.3%,35.3% 38.5%,39.9% 39.8%,40.8% 41.3%,42.7%
Rectum 32.3% 34.6% 38.7% 39.5%
31.7%,32.9% 33.8%,35.4% 38.1%,39.3% 38.7%,40.3%
Liver 3.1% 2.7% 3.6% 3.0%
2.3%,3.9% 1.9%,3.5% 2.9%,4.3% 2.2%,3.8%
Gallbladder 7.5% 8.2% 10.5% 9.2%
6.5%,8.5% 6.9%,9.5% 9.5%,11.5% 7.8%,10.6%
Pancreas 2.7% 1.4% 3.1% 1.6%
2.4%,3% 1.2%,1.6% 2.8%,3.4% 1.4%,1.8%
Larynx 54.8% 55.5% 62.3% 63.0%
53.2%,56.4% 53.6%,57.4% 61%,63.6% 61.2%,64.8%
Lung 5.5% 4.4% 6.4% 5.2%
5.3%,5.7% 4.2%,4.6% 6.3%,6.5% 5%,5.4%
Melanoma of the skin 65.4% 72.7% 77.3% 77.4%
64.2%,66.6% 71.5%,73.9% 76.5%,78.1% 76.3%,78.5%
Breast 50.6% 56.4% 67.1% 68.7%
50.2%,51% 56%,56.8% 66.8%,67.4% 68.3%,69.1%
Cervix 54.2% 60.4% 63.1% 64.6%
53.4%,55% 59.3%,61.5% 62.3%,63.9% 63.5%,65.7%
Uterus 68.6% 69.9% 71.2% 71.7%
67.6%,69.6% 68.5%,71.3% 70.3%,72.1% 70.4%,73%
Ovary 26.1% 27.4% 30.2% 30.4%
25.4%,26.8% 26.4%,28.4% 29.5%,30.9% 29.4%,31.4%
Vagina and vulva 49.0% 49.2% 52.4% 51.7%
46.8%,51.2% 46.3%,52.1% 50.6%,54.2% 49%,54.4%
Prostate 27.9% 28.6% 42.0% 42.3%
27.2%,28.6% 27.9%,29.3% 41.4%,42.6% 41.6%,43%
Testis 87.7% 91.0% 90.6% 91.6%
86.5%,88.9% 89.7%,92.3% 89.7%,91.5% 90.3%,92.9%
Bladder 55.0% 56.2% 62.1% 62.4%
54.2%,55.8% 55.3%,57.1% 61.5%,62.7% 61.6%,63.2%
Kidney 31.4% 34.0% 38.5% 39.7%
30.3%,32.5% 32.7%,35.3% 37.6%,39.4% 38.4%,41%
Brain 9.5% 10.5% 15.4% 14.1%
8.9%,10.1% 9.7%,11.3% 14.7%,16.1% 13.1%,15.1%
Thyroid 66.6% 75.3% 72.4% 76.2%
64.4%,68.8% 72.3%,78.3% 70.6%,74.2% 73.4%,79%
Non-Hodgkin’s lymphoma 35.4% 38.7% 45.5% 46.4%
34.5%,36.3% 37.6%,39.8% 44.8%,46.2% 45.3%,47.5%
Hodgkin’s disease 63.2% 71.3% 73.9% 76.1%
61.7%,64.7% 69.3%,73.3% 72.6%,75.2% 74.2%,78%
Multiple myeloma 8.0% 9.4% 20.0% 21.0%
7.3%,8.7% 8.6%,10.2% 19.1%,20.9% 19.8%,22.2%
All leukaemias 16.4% 19.6% 27.8% 29.1%
15.7%,17.1% 18.6%,20.6% 27%,28.6% 28%,30.2%
Rates derived from England and Wales data for patients diagnosed 1981–1990 (Coleman et al, 1999).
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